GlassScriptPhysician profile
Adam Kachelman
NPI 1659812105
$3,018.51
in general payments reported to CMS, 2019-2025
32 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.45 · 2021: $50.76 · 2022: $87.15 · 2023: $473 · 2024: $1,369 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,864.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $664.56 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $232.63 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $222.13 | 2022-2025 | Verquvo, Belsomra, Gardasil |
| Glaxosmithkline, LLC. | $197.92 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $189.92 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $126.92 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.88 | 2022-2025 | Ofev, Jardiance, Synjardy |
| Abbvie INC. | $105.16 | 2023-2025 | |
| Amgen INC. | $101.54 | 2023-2025 | Repatha, Otezla, Evenity |
| Noven Therapeutics, LLC | $88.01 | 2024-2025 | Xelstrym |
| Otsuka America Pharmaceutical, INC. | $87.07 | 2023-2025 | Rexulti |
| Seqirus USA INC | $86.22 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Astellas Pharma US INC | $85.05 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $76.45 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.91 | 2024-2025 | Caplyta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $69.51 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.58 | 2023-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $63.19 | 2024 | |
| Philips North America LLC | $54.49 | 2025 | Ecc Solutions |
| Daiichi Sankyo INC. | $45.69 | 2023 | Injectafer |
| Lundbeck LLC | $42.33 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $39.59 | 2023-2025 | Cologuard Collection Kit |
| Radius Health, INC. | $26.60 | 2025 | Tymlos |
| Kyowa Kirin, INC. | $20.23 | 2023 | Crysvita |
| Lilly USA, LLC | $19.53 | 2025 | Zepbound |
| Verona Pharma, INC. | $19.09 | 2025 | Ohtuvayre |
| Novavax INC | $18.21 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Sanofi-Aventis U.S. LLC | $16.45 | 2020 | |
| Mannkind Corporation | $15.77 | 2024 | |
| Abbott Laboratories | $15.67 | 2025 | Freestyle Libre |
| Sanofi Pasteur INC. | $13.83 | 2025 | |
| Ascensia Diabetes Care US INC. | $13.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Kachelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.